Icon
+91 94997 68112
Login Register

Quillichew ER - (20, 30, 40 mg; Tablet, Extended Release, Chewable)

Methylphenidate Hydrochloride Tris pharma
20, 30, 40 mg; Tablet, Extended Release, Chewable
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
QuilliChew ER is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Yes
******* ** *** ***** ** **** **** ** **** ******* ’***- *** **, ****, ’***- *** **, ****, ’***- *** **, **** *** ’***- *** **, **** *** *** ************ ********* ** **** ******. ** ****** **** **** ******* ******* ** *** ****. ******* ***** **** **** ***** *** ******* ******** *** ******** ** ****. ** ** ******* **** **** ****'* **** ****** ******* ** *******. ***** ** **** ****** **** ** ****** ****** ** ******* '***, '***, '*** *** '***.
Quillichew ER Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10
******* *** ********* *** ********* *** ********* *** ********* **** ** ***** **, **** **** ** ***** **, **** **** ** ***** **, **** *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******)
****** *** ********* *** ********* ******* ******* ******* ******* *** ********* *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******)
**** *** ********* *** ********* *** ********* *** ********* **** ** ** **** ** ** **** ** ** *** ********* **** ** ** **** ** **
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* ***\ ** *** **, **** ******* **** *** ****** *** ****
****** ** \ ** *** **, **** ******* ********* ******** ******* *** **** *** *** ****
**** ** \ ** *** **, **** **** ** ** ********* ******** *** ****** *** **, ****
  1. **** *, **** : ******* ******** **** ****** ***** *** **** ** **** ******* ’*** (*** **, ****), ’*** (*** **, ****), ’*** (*** **, ****) *** ’*** (*** **, ****).
  2. *** **, **** : **** ***** * **** ******* ******* ** ******** ***** ** ********.
  3. *** **, **** : **** ****** **** ******* ************** ** ****** ** '***, '*** *** '***
  4. *** *, **** : **** ******* ******* **************** ******.
  5. *** **, **** : **** ******** **** ***** *** ****-** ****** **** ******* '***, '***, '***, '***, '***, *** '***
  6. *** **, **** : **** **** **** **** ************ ** ******* '***, '*** *** '***
  7. *** **, **** : **** ****** **** ****** ************** ** ****** ** '***, '***, '*** *** '***
  8. *** **, **** : **** **** **** **** ************ ** ***** ****** ******* '*** *** '***.
  9. *** **, **** : **** **** *** **** ** *** ******** ***** (**) ***** **** ****'* **** ******* ********* ****' ******* '***, '***, '***, '*** *** '***
  10. *** **, **** : **** ****** *** ****** ******* ********** ** ******* *****
  11. *** **, **** : **** ******** ** *** ******* ******* (**) **** *** **'* ********, ******* **** ******.
  12. *** **, **** : **** ********* *** ** ****** ******* **** ******.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.